# Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

> **NCT05229614** · PHASE2 · RECRUITING · sponsor: **CNAO National Center of Oncological Hadrontherapy** · enrollment: 27 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Urothelial Carcinoma

## Interventions

- **RADIATION:** Carbon Ion Therapy
- **DRUG:** Immunotherapy (Pembrolizumab)

## Key facts

- **NCT ID:** NCT05229614
- **Lead sponsor:** CNAO National Center of Oncological Hadrontherapy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-26
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05229614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05229614, "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05229614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*